ピリドスチグミン
臭化ピリドスチグミンは合成第四級アンモニウム抗コリンエステラーゼ薬であり、獣医学では主に犬（まれに猫）の**重症筋無力症（MG）**の管理に使用されます。 * **臨床のポイント：** 第四級アンモニウム構造を持つため、標準的な治療用量では血液脳関門を容易に通過しません。そのため、中枢神経系（CNS）の副作用を引き起こすことなく、MGのような末梢神経筋接合部疾患を標的とするのに理想的です。 * 一般に、先天性のMGよりも**後天性重症筋無力症**に対してはるかに有効であると考えられています。 * 吸収が不安定で治療域が狭いため、筋力の改善とコリン作動性毒性のリスクのバランスを取りながら、効果を見極めて慎重に用量を調整する必要があります。
作用機序: **Pyridostigmine** acts as a reversible, competitive inhibitor of the enzyme **acetylcholinesterase (AChE)** at the neuromuscular junction. * **Mechanism:** Pyridostigmine competes directly with **acetylcholine (ACh)** for attachment to AChE. The resulting pyridostigmine-AChE complex is hydrolyzed much more slowly than the natural ACh-AChE complex. * **Pathway:** Inhibition of AChE → Decreased breakdown of ACh → Accumulation of ACh in the synaptic cleft → Prolonged and increased stimulation of **nicotinic ACh receptors** on the motor endplate → Enhanced skeletal muscle contraction and improved strength in myasthenic patients.
動物種別の用量
- Myasthenia gravis (MG) · 0.5-3 mg/kg daily PO in divided doses · PO · Divided daily · Dose depending on response.
- Myasthenia gravis (MG) · 1-3 mg/kg PO q8-12h · PO · q8-12h
- Myasthenia gravis (MG) · 0.5-3 mg/kg PO per day · PO · Daily · Given with corticosteroids.
- Myasthenia gravis · 0.25 mg/kg · PO · q8-12h
- Myasthenia gravis (MG) · 1-3 mg/kg PO q8-12h. For animals that cannot tolerate oral medications, it may be used as an IV constant rate infusion at 0.01-0.03 mg/kg/hour. · PO/IV · q8-12h or CRI · Titrate to effect to minimize adverse effects and maximize muscle strength.
- Myasthenia gravis (MG) · 0.5-3 mg/kg PO q8-12 hours with food. · PO · q8-12h · Start low and increase slowly. Liquid formulation recommended for easy adjustment. An H2 antagonist (e.g., famotidine 5 mg/kg/day) may reduce nausea/GI irritation.
- Acquired Myasthenia gravis (MG) · 7.5-30 mg PO two times a day. · PO · BID · Begin after oral regurgitation is abolished with parenteral neostigmine. Once stable, begin corticosteroids for 2 weeks, then gradually reduce pyridostigmine.
- Myasthenia gravis (MG) · 0.5-3 mg/kg PO two to three times a day. · PO · BID-TID · If no response, add prednisone.
- Myasthenia gravis (MG) · 0.5-1 mg/kg PO two to three times a day · PO · BID-TID · With or without prednisone (2 mg/kg PO twice daily). Spontaneous remission is not uncommon.
投与経路
禁忌
- Hypersensitivity to anticholinesterase compounds or bromides
- Mechanical or physical obstructions of the urinary tract
- Mechanical or physical obstructions of the gastrointestinal (GI) tract
- Mechanical gastrointestinal obstruction
- Mechanical urinary tract obstruction
- Peritonitis
有害事象
- Nausea
- Vomiting
- Diarrhea
- Excessive salivation (ptyalism)
- Sweating (in species with sweat glands)
- Increased bronchial secretions
- Bronchospasm
- Pulmonary edema
- Respiratory paralysis
- Miosis (pupil constriction)
- Blurred vision
- Lacrimation (tearing)
- Bradycardia
- Tachycardia
- Cardiospasm
- Hypotension
- Cardiac arrest
薬物相互作用
- Atropine · Antagonizes the muscarinic effects of pyridostigmine. Use cautiously as it can mask early clinical signs of a life-threatening cholinergic crisis.
- Corticosteroids · May decrease the anticholinesterase activity of pyridostigmine. Discontinuing corticosteroids may suddenly increase anticholinesterase activity, requiring dose adjustments.
- Dexpanthenol · Theoretically may have additive cholinergic effects when used concurrently.
- Neuromuscular blocking drugs (e.g., aminoglycosides) · May necessitate increased dosages of pyridostigmine when treating or diagnosing myasthenic patients.
- Magnesium (parenteral) · Can antagonize anticholinesterase therapy due to its direct depressant effect on skeletal muscle.
- Muscle Relaxants · May prolong the Phase I block of depolarizing muscle relaxants (e.g., succinylcholine) and antagonize the actions of non-depolarizing agents (e.g., pancuronium, atracurium).
- Aminoglycosides · May antagonize the neuromuscular effects of pyridostigmine · moderate
- Clindamycin · May antagonize the neuromuscular effects of pyridostigmine · moderate
- Lincomycin · May antagonize the neuromuscular effects of pyridostigmine · moderate
- Propranolol · May antagonize the effects of pyridostigmine · moderate
- Suxamethonium · Pyridostigmine may enhance the effect of depolarizing muscle relaxants · major
モニタリング
- Clinical signs of cholinergic toxicity (salivation, lacrimation, urination, defecation, GI upset, emesis, weakness)
- Efficacy of therapy (improvement in muscle strength, reduction of megaesophagus/regurgitation)
- Respiratory rate and effort
- Improvement in muscle strength and exercise tolerance
- Signs of muscarinic toxicity (hypersalivation, vomiting, diarrhea, miosis)
- Heart rate and rhythm
- Respiratory rate and effort (especially in patients with megaoesophagus)
過量投与
Overdosage of pyridostigmine can induce a life-threatening **cholinergic crisis**. * **Clinical Signs (SLUDGE syndrome):** GI effects (nausea, vomiting, diarrhea), excessive salivation, sweating, respiratory distress (increased bronchial secretions, bronchospasm, pulmonary edema, respiratory paralysis), ophthalmic effects (miosis, blurred vision, lacrimation), cardiovascular collapse (bradycardia, tachycardia, hypotension, cardiac arrest), severe muscle cramps, and profound weakness. * **Diagnostic Challenge:** Overdoses in myasthenic patients can be very difficult to distinguish from a **myasthenic crisis** (disease exacerbation). The time of onset of clinical signs or an **edrophonium challenge** (Tensilon test) may help differentiate the two. * **Treatment:** Consists of immediate respiratory and cardiac supportive therapy. **Atropine** should be administered to antagonize muscarinic effects (refer to atropine protocols for cholinergic toxicity).
VetSheet の薬剤リファレンスは、獣医療従事者向けの臨床意思決定支援を目的としており、専門的判断やメーカーの最新添付文書に代わるものではありません。